Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006451 | Bone Marrow Transplantation in Treating Patients With Leukemia | withdrawn | Phase 3 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer(ATTILA) | withdrawn | Phase 3 | 0 | iOMEDICO AGINDUSTRY | 1 | Nov 26, 2019 |
| clinicaltrials |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 22, 2019 | clinicaltrials |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma(LD-FOX4/HCC) | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | withdrawn | Phase 3 | 0 | Italian Sarcoma GroupNETWORK | 1 | May 13, 2019 | clinicaltrials |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer | withdrawn | Phase 3 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03717038 | Sym004 Versus TAS-102 in Patients With mCRC | withdrawn | Phase 3 | 0 | Symphogen A/SINDUSTRY | 0 | Feb 4, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03355768 | Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | withdrawn | Phase 3 | 0 | Jennifer AmengualOTHER | 0 | Dec 19, 2018 | clinicaltrials |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 15, 2018 | clinicaltrials |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | withdrawn | Phase 3 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT03048136 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer(CheckMate 955) | withdrawn | Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 5 | Apr 17, 2018 | clinicaltrials |
| NCT02155634 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 0 | Apr 10, 2018 | clinicaltrials |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma | withdrawn | Phase 3 | 0 | University of LouisvilleOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02736435 | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | withdrawn | Phase 3 | 0 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | withdrawn | Phase 3 | 0 | Heidelberg Pharma AGINDUSTRY | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01260103 | Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma | withdrawn | Phase 3 | 0 | Burzynski Research InstituteOTHER | 0 | Jul 26, 2017 | clinicaltrials |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases(BOS3) | withdrawn | Phase 2 / Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT03070691 | Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | withdrawn | Phase 2 / Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 10 | May 5, 2017 | clinicaltrials |
| NCT02795884 | Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation | withdrawn | Phase 3 | 0 | Yonsei UniversityOTHER | 0 | Dec 30, 2016 | clinicaltrials |
| NCT02427893 | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | withdrawn | Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Genentech, Inc.INDUSTRY | 0 | Oct 19, 2016 | clinicaltrials |
| NCT01961934 | C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression | withdrawn | Phase 2 / Phase 3 | 0 | Phoenix Molecular ImagingOTHER | 1 | Sep 28, 2016 | clinicaltrials |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Acerta Pharma BVINDUSTRY | 0 | May 13, 2016 | clinicaltrials |
| NCT02004210 | A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma | withdrawn | Phase 3 | 0 | Seoul National University HospitalOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01830101 | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | withdrawn | Phase 3 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01058902 | The Effect Of Aspirin On Survival in Lung Cancer | withdrawn | Phase 3 | 0 | Liverpool Heart and Chest Hospital NHS Foundation TrustOTHER | 1 | Mar 7, 2016 | clinicaltrials |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | withdrawn | Phase 3 | 0 | Asan Medical CenterOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01067274 | ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)(ALFA-0703) | withdrawn | Phase 3 | 0 | Acute Leukemia French AssociationOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT02511600 | Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication | withdrawn | Phase 3 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 15, 2015 | clinicaltrials |
| NCT00411281 | Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder | withdrawn | Phase 3 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 30, 2015 | clinicaltrials |
| NCT00735241 | FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma(FAST) | withdrawn | Phase 2 / Phase 3 | 0 | Sirtex MedicalINDUSTRY | 1 | May 22, 2015 | clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT01386398 | Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 21, 2015 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT00874302 | Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms | withdrawn | Phase 3 | 0 | Repros Therapeutics Inc.INDUSTRY | 2 | Jun 27, 2014 | clinicaltrials |
| NCT00907504 | Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer(ADVIGO1017) | withdrawn | Phase 3 | 0 | PfizerINDUSTRY | 0 | Jun 17, 2014 | clinicaltrials |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer(FACT2) | withdrawn | Phase 3 | 0 | Mateon TherapeuticsINDUSTRY | 0 | May 1, 2014 | clinicaltrials |
| NCT01776892 | Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease | withdrawn | Phase 3 | 0 | University of AlbertaOTHER | 1 | Apr 8, 2014 | clinicaltrials |
| NCT01326078 | Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures. | withdrawn | Phase 2 / Phase 3 | 0 | Cristália Produtos Químicos Farmacêuticos Ltda.INDUSTRY | 0 | Mar 26, 2014 | clinicaltrials |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | withdrawn | Phase 3 | 0 | Eisai Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00943709 | Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia | withdrawn | Phase 3 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 30, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jan 3, 2020source: clinicaltrials